Stock Track | Enliven Therapeutics Soars 5.93% Following Bullish Analyst Ratings

Stock Track

Aug 14, 2025

Enliven Therapeutics (ELVN) shares are soaring 5.93% in pre-market trading on Thursday, buoyed by recent bullish analyst ratings. The surge comes on the heels of two prominent Wall Street firms reaffirming their positive outlook on the biotech company.

BTIG analyst Justin Zelin reiterated a Buy rating on Enliven Therapeutics early Thursday, setting an ambitious price target of $45.00. This target suggests significant upside potential from the stock's previous closing price of $19.99. Additionally, TD Cowen analyst Phil Nadeau maintained his Buy rating on the company in a report released late Wednesday.

The back-to-back bullish ratings from respected analysts appear to have boosted investor confidence in Enliven Therapeutics' prospects. As the biotech sector continues to attract attention, ELVN's strong pre-market performance indicates that market participants are responding positively to the analysts' optimistic views on the company's future.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1119470373"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1119470373\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1119470373?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-14 21:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1119470373","market":"us","top_or_hot":-1,"title":"Stock Track | Enliven Therapeutics Soars 5.93% Following Bullish Analyst Ratings","media":"Stock Track","content":"<p>Enliven Therapeutics (ELVN) shares are soaring 5.93% in pre-market trading on Thursday, buoyed by recent bullish analyst ratings. The surge comes on the heels of two prominent Wall Street firms reaffirming their positive outlook on the biotech company.</p>\n\n<p>BTIG analyst Justin Zelin reiterated a Buy rating on Enliven Therapeutics early Thursday, setting an ambitious price target of $45.00. This target suggests significant upside potential from the stock's previous closing price of $19.99. Additionally, TD Cowen analyst Phil Nadeau maintained his Buy rating on the company in a report released late Wednesday.</p>\n\n<p>The back-to-back bullish ratings from respected analysts appear to have boosted investor confidence in Enliven Therapeutics' prospects. As the biotech sector continues to attract attention, ELVN's strong pre-market performance indicates that market participants are responding positively to the analysts' optimistic views on the company's future.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Enliven Therapeutics Soars 5.93% Following Bullish Analyst Ratings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Enliven Therapeutics Soars 5.93% Following Bullish Analyst Ratings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-08-14 21:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Enliven Therapeutics (ELVN) shares are soaring 5.93% in pre-market trading on Thursday, buoyed by recent bullish analyst ratings. The surge comes on the heels of two prominent Wall Street firms reaffirming their positive outlook on the biotech company.</p>\n\n<p>BTIG analyst Justin Zelin reiterated a Buy rating on Enliven Therapeutics early Thursday, setting an ambitious price target of $45.00. This target suggests significant upside potential from the stock's previous closing price of $19.99. Additionally, TD Cowen analyst Phil Nadeau maintained his Buy rating on the company in a report released late Wednesday.</p>\n\n<p>The back-to-back bullish ratings from respected analysts appear to have boosted investor confidence in Enliven Therapeutics' prospects. As the biotech sector continues to attract attention, ELVN's strong pre-market performance indicates that market participants are responding positively to the analysts' optimistic views on the company's future.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ELVN","symbol_name":"Enliven Treateutics","start_time":0,"source_url":"","article_id":"1119470373","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1119470373","pubTimestamp":1755178584,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Enliven Therapeutics (ELVN) shares are soaring 5.93% in pre-market trading on Thursday, buoyed by recent bullish analyst ratings. The surge comes on the heels of two prominent Wall Street firms...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ELVN":"Enliven Treateutics"},"translate_title":"股票追踪|Enliven Therapeutics在分析师看涨评级后飙升5.93%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ELVN":1},"content_text":"Enliven Therapeutics (ELVN) shares are soaring 5.93% in pre-market trading on Thursday, buoyed by recent bullish analyst ratings. The surge comes on the heels of two prominent Wall Street firms reaffirming their positive outlook on the biotech company.\nBTIG analyst Justin Zelin reiterated a Buy rating on Enliven Therapeutics early Thursday, setting an ambitious price target of $45.00. This target suggests significant upside potential from the stock's previous closing price of $19.99. Additionally, TD Cowen analyst Phil Nadeau maintained his Buy rating on the company in a report released late Wednesday.\nThe back-to-back bullish ratings from respected analysts appear to have boosted investor confidence in Enliven Therapeutics' prospects. As the biotech sector continues to attract attention, ELVN's strong pre-market performance indicates that market participants are responding positively to the analysts' optimistic views on the company's future.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}